Abstract:Proteolysis-targeting chimeras (PROTACs) technology has garnered significant attention over the last 10 years, representing a burgeoning therapeutic approach with the potential to address pathogenic proteins that have historically posed challenges for traditional small-molecule inhibitors. PROTACs exploit the endogenous E3 ubiquitin ligases to facilitate degradation of the proteins of interest (POIs) through the ubiquitin–proteasome system (UPS) in a cyclic catalytic manner. Despite recent endeavors to advance the utilization of PROTACs in clinical settings, the majority of PROTACs fail to progress beyond the preclinical phase of drug development. There are multiple factors impeding the market entry of PROTACs, with the insufficiently precise degradation of favorable POIs standing out as one of the most formidable obstacles. Recently, there has been exploration of new-generation advanced PROTACs, including small-molecule PROTAC prodrugs, biomacromolecule-PROTAC conjugates, and nano-PROTACs, to improve the in vivo efficacy of PROTACs. These improved PROTACs possess the capability to mitigate undesirable physicochemical characteristics inherent in traditional PROTACs, thereby enhancing their targetability and reducing off-target side effects. The new-generation of advanced PROTACs will mark a pivotal turning point in the realm of targeted protein degradation. In this comprehensive review, we have meticulously summarized the state-of-the-art advancements achieved by these cutting-edge PROTACs, elucidated their underlying design principles, deliberated upon the prevailing challenges encountered, and provided an insightful outlook on future prospects within this burgeoning field.

Back Cover: Aptamer‐PROTAC Conjugates (apcs) for Tumor‐Specific Targeting in Breast Cancer (angew. Chem. Int. Ed. 43/2021)

Rücktitelbild: Aptamer‐PROTAC Conjugates (apcs) for Tumor‐Specific Targeting in Breast Cancer (angew. Chem. 43/2021)

Aptamer-PROTAC Conjugates (APCs) for Tumor-specific Targeting in Breast Cancer.

Drugtamer‐PROTAC Conjugation Strategy for Targeted PROTAC Delivery and Synergistic Antitumor Therapy

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

Cooperatively Designed Aptamer-PROTACs for Spatioselective Degradation of Nucleocytoplasmic Shuttling Protein for Enhanced Combinational Therapy

PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Recent Advances in the Design and Development of Anticancer Molecules Based on PROTAC Technology.

Recent Progress of Aptamer‒drug Conjugates in Cancer Therapy

Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras Through Irgd Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.

Advances in the Development of Aptamer Drug Conjugates for Targeted Drug Delivery.

Advances In The Development Of Aptamer Drug Conjugates For Targeted Drug Delivery

PROTAC: A Promising Technology for Cancer Treatment

Recent Advances in PROTACs for Drug Targeted Protein Research

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

PROTAC: novel degradable approach for different targets to treat breast cancer

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

A Self-Assembled Affibody-Protac Conjugate Nanomedicine for Targeted Cancer Therapy

A Cocktail Therapeutic Strategy Based on Clofarabine-Containing Aptamer-PROTAC for Enhanced Cancer Therapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy